14 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18561553 | COMPOUND USED AS BCR-ABL INHIBITOR | BORALSKY, LUKE ALAN | 1624 | Non-Final OA | Nov 16, 2023 |
| 18275142 | BISPECIFIC ANTIBODY | NICKOL, GARY B | 1643 | Non-Final OA | Jul 31, 2023 |
| 18263293 | TYK2 INHIBITOR COMPOUND CONTAINING BICYCLIC RING | LEE, CHIHYI NMN | 1628 | Non-Final OA | Jul 27, 2023 |
| 18037523 | DEUTERIUM-MODIFIED THIENOPYRIDONE COMPOUND | HAVLIN, ROBERT H | 1626 | Non-Final OA | May 17, 2023 |
| 17922336 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | DAHLIN, HEATHER RAQUEL | 1629 | Non-Final OA | May 01, 2023 |
| 18020584 | SINGLE VARIABLE DOMAIN AND ANTIGEN BINDING MOLECULE BINDING BCMA | O'BRIEN, LEA S | 1646 | Non-Final OA | Feb 09, 2023 |
| 18019612 | COMBINED MEDICATION FOR TREATING SOFT TISSUE SARCOMA | KAUFMAN, CLAIRE M | 1674 | Non-Final OA | Feb 03, 2023 |
| 18001244 | CONJUGATE OF DOUBLE-STRANDED SIRNA ANALOGUE | ZAHORIK, AMANDA MARY | 1636 | Non-Final OA | Dec 08, 2022 |
| 17922230 | ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOF | BRISTOL, LYNN ANNE | 1643 | Final Rejection | Oct 28, 2022 |
| 17792282 | PHARMACEUTICAL COMPOSITION OF TRICYCLIC PDE3/PDE4 DUAL INHIBITOR COMPOUND | HUANG, GIGI GEORGIANA | 1613 | Final Rejection | Jul 12, 2022 |
| 17792192 | CRYSTAL OF PDE3/PDE4 DUAL INHIBITOR AND USE THEREOF | BELL, SARA ELIZABETH | 1625 | Final Rejection | Jul 12, 2022 |
| 17595519 | QUINOLINE DERIVATIVE USED FOR COMBINATION TREATMENT OF SMALL CELL LUNG CANCER | CHEN, PO-CHIH | 1621 | Non-Final OA | Nov 18, 2021 |
| 17603886 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | MCMILLIAN, KARA RENITA | 1623 | Non-Final OA | Oct 14, 2021 |
| 17436991 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | MAHLUM, JONATHAN DAVIS | 1625 | Final Rejection | Sep 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial